{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:12:28Z","timestamp":1745381548031,"version":"3.40.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10147-025-02744-y","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T01:33:47Z","timestamp":1742780027000},"page":"878-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-7436","authenticated-orcid":false,"given":"Tomoki","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2744_CR1","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1002\/cncr.24424","volume":"115","author":"A Ferrari","year":"2009","unstructured":"Ferrari A, Rodriquez-Galindo C, Saab R et al (2009) Comparing children and adults with synovial sarcoma in the surveillance, epidemiology and end results program, 1983 to 2005. Cancer 115:3537\u20133547. https:\/\/doi.org\/10.1002\/cncr.24424","journal-title":"Cancer"},{"key":"2744_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/jjco\/hyab039","volume":"51","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Saito Y, Tsuchiya K et al (2021) Is perioperative chemotherapy recommended in childhood and adolescent patients with synovial sarcoma? A systematic review. Jpn J Clin Oncol 51:927\u2013931. https:\/\/doi.org\/10.1093\/jjco\/hyab039","journal-title":"Jpn J Clin Oncol"},{"key":"2744_CR3","unstructured":"JOA Musculoskeletal Tumor Committee (2021) Soft tissue tumor registry in Japan. National Cancer Center, Tokyo"},{"key":"2744_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.anndiagpath.2014.09.002","volume":"18","author":"K Thway","year":"2014","unstructured":"Thway K, Fisher C (2014) Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol 18:369\u2013380. https:\/\/doi.org\/10.1016\/j.anndiagpath.2014.09.002","journal-title":"Ann Diagn Pathol"},{"key":"2744_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.2017.75.1941","volume":"36","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti S, Van Tine BA (2018) Synovial sarcoma: current concepts and future perspectives. J Clin Oncol 36:180\u2013187. https:\/\/doi.org\/10.1200\/JCO.2017.75.1941","journal-title":"J Clin Oncol"},{"key":"2744_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s1092-9134(98)80042-7","volume":"2","author":"C Fisher","year":"1998","unstructured":"Fisher C (1998) Synovial sarcoma. Ann Diagn Pathol 2:401\u2013421. https:\/\/doi.org\/10.1016\/s1092-9134(98)80042-7","journal-title":"Ann Diagn Pathol"},{"key":"2744_CR7","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.esmoop.2023.101618","volume":"8","author":"JY Blay","year":"2023","unstructured":"Blay JY, von Mehren M, Jones RL et al (2023) Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies. ESMO Open 8:101618","journal-title":"ESMO Open"},{"key":"2744_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/jso.25417","volume":"119","author":"H Outani","year":"2019","unstructured":"Outani H, Nakamura T, Murata H et al (2019) Localized synovial sarcoma: a single institutional study of 191 patients with a minimum follow-up of 5 years for survivors. J Surg Oncol 119:850\u2013855. https:\/\/doi.org\/10.1002\/jso.25417","journal-title":"J Surg Oncol"},{"key":"2744_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/bjc.2015.375","volume":"113","author":"M Vlenterie","year":"2015","unstructured":"Vlenterie M, Ho VKY, Kaal SEJ et al (2015) Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer 113:1602\u20131606. https:\/\/doi.org\/10.1038\/bjc.2015.375","journal-title":"Br J Cancer"},{"key":"2744_CR10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/curroncol28030177","volume":"28","author":"AM Gazendam","year":"2021","unstructured":"Gazendam AM, Popovic S, Munir S et al (2021) Synovial sarcoma: a clinical review. Curr Oncol 28:1909\u20131920. https:\/\/doi.org\/10.3390\/curroncol28030177","journal-title":"Curr Oncol"},{"key":"2744_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jor.2023.07.002","volume":"42","author":"F Sacchetti","year":"2023","unstructured":"Sacchetti F, Alsina AC, Muratori F et al (2023) Tumor size and surgical margins are important prognostic factors of synovial sarcoma\u2014a retrospective study. J Orthop 42:74\u201379. https:\/\/doi.org\/10.1016\/j.jor.2023.07.002","journal-title":"J Orthop"},{"key":"2744_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jos.2021.09.012","volume":"28","author":"Y Hagiwara","year":"2023","unstructured":"Hagiwara Y, Iwata S, Ogura K et al (2023) Clinical analysis of multimodal treatment for localized synovial sarcoma: A multicenter retrospective study. J Orthop Sci 28:261\u2013266. https:\/\/doi.org\/10.1016\/j.jos.2021.09.012","journal-title":"J Orthop Sci"},{"key":"2744_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/annonc\/mdq394","volume":"22","author":"AH Krieg","year":"2011","unstructured":"Krieg AH, Hefti F, Speth BM et al (2011) Synovial sarcomas usually metastasize after > 5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol 22:458\u2013467. https:\/\/doi.org\/10.1093\/annonc\/mdq394","journal-title":"Ann Oncol"},{"key":"2744_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/annonc\/mdi082","volume":"16","author":"EL Spurrell","year":"2005","unstructured":"Spurrell EL, Fisher C, Thomas JM et al (2005) Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 16:437\u2013444. https:\/\/doi.org\/10.1093\/annonc\/mdi082","journal-title":"Ann Oncol"},{"key":"2744_CR15","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1002\/cam4.3039","volume":"9","author":"SM Pollack","year":"2020","unstructured":"Pollack SM, Somaiah N, Araujo DM et al (2020) Clinical outcomes of patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med 9:4593\u20134602. https:\/\/doi.org\/10.1002\/cam4.3039","journal-title":"Cancer Med"},{"key":"2744_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","volume":"20","author":"M von Mehren","year":"2022","unstructured":"von Mehren M, Kane JM, Agulnik M et al (2022) Soft tissue sarcoma, version 2.2022, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw 20:815\u2013833","journal-title":"J Natl Compr Canc Netw"},{"key":"2744_CR17","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP et al (2021) Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol 32:1348\u20131365. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.006","journal-title":"Ann Oncol"},{"key":"2744_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2217\/fon-2022-1005","volume":"19","author":"N Patel","year":"2023","unstructured":"Patel N, Pokras S, Ferma J et al (2023) Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the UK. Future Oncol 19:1261\u20131275. https:\/\/doi.org\/10.2217\/fon-2022-1005","journal-title":"Future Oncol"},{"key":"2744_CR19","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.2217\/fon-2022-0477","volume":"18","author":"S Pokras","year":"2022","unstructured":"Pokras S, Tseng WY, Espirito JL et al (2022) Treatment patterns and outcomes in metastatic synovial sarcoma: a real-world study in the US oncology network. Future Oncol 18:3637\u20133650. https:\/\/doi.org\/10.2217\/fon-2022-0477","journal-title":"Future Oncol"},{"key":"2744_CR20","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27:3126\u20133132. https:\/\/doi.org\/10.1200\/JCO.2008.21.3223","journal-title":"J Clin Oncol"},{"key":"2744_CR21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/cncr.29961","volume":"122","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Matsumine A, Kawai A et al (2016) The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122:1408\u20131416. https:\/\/doi.org\/10.1002\/cncr.29961","journal-title":"Cancer"},{"key":"2744_CR22","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","volume":"48","author":"A Le Cesne","year":"2012","unstructured":"Le Cesne A, Cresta S, Maki RG et al (2012) A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer 48:3036\u20133044. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.012","journal-title":"Eur J Cancer"},{"key":"2744_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/CAD.0000000000000228","volume":"26","author":"R Sanfilippo","year":"2015","unstructured":"Sanfilippo R, Dileo P, Blay JY (2015) Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs 26:678\u2013681. https:\/\/doi.org\/10.1097\/CAD.0000000000000228","journal-title":"Anticancer Drugs"},{"key":"2744_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","volume":"12","author":"P Sch\u00f6ffski","year":"2011","unstructured":"Sch\u00f6ffski P, Ray-Coquard IL, Cioffi A et al (2011) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 12:1045\u20131052. https:\/\/doi.org\/10.1016\/S1470-2045(11)70230-3","journal-title":"Lancet Oncol"},{"key":"2744_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10585-019-09980-3","volume":"36","author":"T Nakamura","year":"2019","unstructured":"Nakamura T, Tsukushi S, Asanuma K et al (2019) The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study. Clin Exp Metastasis 36:343\u2013350. https:\/\/doi.org\/10.1007\/s10585-019-09980-3","journal-title":"Clin Exp Metastasis"},{"key":"2744_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12032-018-1193-5","volume":"35","author":"A Pender","year":"2018","unstructured":"Pender A, Davis EJ, Chauhan D et al (2018) Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol 35:131. https:\/\/doi.org\/10.1007\/s12032-018-1193-5","journal-title":"Med Oncol"},{"issue":"Suppl 1","key":"2744_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3747\/co.27.5407","volume":"27","author":"O Ayodele","year":"2020","unstructured":"Ayodele O, Razak ARA (2020) Immunotherapy in soft-tissue sarcoma. Curr Oncol 27(Suppl 1):17\u201323. https:\/\/doi.org\/10.3747\/co.27.5407","journal-title":"Curr Oncol"},{"key":"2744_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/imt.14.98","volume":"7","author":"M Mata","year":"2015","unstructured":"Mata M, Gottschalk S (2015) Adoptive cell therapy for sarcoma. Immunotherapy 7:21\u201335. https:\/\/doi.org\/10.2217\/imt.14.98","journal-title":"Immunotherapy"},{"key":"2744_CR29","doi-asserted-by":"publisher","first-page":"101159","DOI":"10.1016\/j.xcrm.2023.101159","volume":"4","author":"R Al-Marayaty","year":"2023","unstructured":"Al-Marayaty R, Pollack SM (2023) Pushing forward in sarcoma with a new TCR targeting NY-ESO-1. Cell Rep Med 4:101159. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101159","journal-title":"Cell Rep Med"},{"key":"2744_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2217\/imt-2016-0026","volume":"8","author":"M Dallos","year":"2016","unstructured":"Dallos M, Tap WD, D\u2019Angelo SP (2016) Current status of engineered T-cell therapy for synovial sarcoma. Immunotherapy 8:1073\u20131080. https:\/\/doi.org\/10.2217\/imt-2016-0026","journal-title":"Immunotherapy"},{"key":"2744_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/modpathol.2012.31","volume":"25","author":"JP Lai","year":"2012","unstructured":"Lai JP, Robbins PF, Raffeld M et al (2012) NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 25:854\u2013858. https:\/\/doi.org\/10.1038\/modpathol.2012.31","journal-title":"Mod Pathol"},{"key":"2744_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ijc.1451","volume":"94","author":"AA Jungbluth","year":"2001","unstructured":"Jungbluth AA, Antonescu CR, Busam KJ et al (2001) Monophasic and biphasic synovial sarcomas abundantly express cancer\/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 94:252\u2013256. https:\/\/doi.org\/10.1002\/ijc.1451","journal-title":"Int J Cancer"},{"key":"2744_CR33","doi-asserted-by":"publisher","first-page":"101265","DOI":"10.1016\/j.omtm.2024.101265","volume":"32","author":"T Wang","year":"2024","unstructured":"Wang T, Navenot JM, Rafail S et al (2024) Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A*02-eligible patients. Mol Ther Methods Clin Dev 32:101265. https:\/\/doi.org\/10.1016\/j.omtm.2024.101265","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2744_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/modpathol.2014.155","volume":"28","author":"M Endo","year":"2015","unstructured":"Endo M, de Graaff MA, Ingram DR et al (2015) NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28:587\u2013595. https:\/\/doi.org\/10.1038\/modpathol.2014.155","journal-title":"Mod Pathol"},{"key":"2744_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00428-017-2206-z","volume":"471","author":"K Iura","year":"2017","unstructured":"Iura K, Kohashi K, Ishii T et al (2017) MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1. Virchows Arch 471:383\u2013392. https:\/\/doi.org\/10.1007\/s00428-017-2206-z","journal-title":"Virchows Arch"},{"key":"2744_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","volume":"61","author":"K Iura","year":"2017","unstructured":"Iura K, Maekawa A, Kohashi K et al (2017) Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol 61:130\u2013139. https:\/\/doi.org\/10.1016\/j.humpath.2016.12.006","journal-title":"Hum Pathol"},{"key":"2744_CR37","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917\u2013924. https:\/\/doi.org\/10.1200\/JCO.2010.32.2537","journal-title":"J Clin Oncol"},{"key":"2744_CR38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21:1019\u20131027. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2708","journal-title":"Clin Cancer Res"},{"key":"2744_CR39","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS et al (2018) Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259 cells in synovial sarcoma. Cancer Discov 8:944\u2013957. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1417","journal-title":"Cancer Discov"},{"key":"2744_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","volume":"7","author":"I Ramachandran","year":"2019","unstructured":"Ramachandran I, Lowther DE, Dryer-Minnerly R et al (2019) Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer 7:276. https:\/\/doi.org\/10.1186\/s40425-019-0762-2","journal-title":"J Immunother Cancer"},{"key":"2744_CR41","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J et al (2023) Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A*02:01 patients with advanced soft tissue sarcoma. Cell Rep Med 4:101133. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101133","journal-title":"Cell Rep Med"},{"key":"2744_CR42","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-18-3496","volume":"25","author":"TS Nowicki","year":"2019","unstructured":"Nowicki TS, Berent-Maoz B, Cheung-Lau G et al (2019) A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab. Clin Cancer Res 25:2096\u20132108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3496","journal-title":"Clin Cancer Res"},{"key":"2744_CR43","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","volume":"29","author":"A Kawai","year":"2023","unstructured":"Kawai A, Ishihara M, Nakamura T et al (2023) Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: a phase I\/II clinical trial. Clin Cancer Res 29:5069\u20135078. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1456","journal-title":"Clin Cancer Res"},{"key":"2744_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Van Tine BA, Biswas S (2023) Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients; phase 1 trial. Nat Med 29:104\u2013114. https:\/\/doi.org\/10.1038\/s41591-022-02128-z","journal-title":"Nat Med"},{"key":"2744_CR45","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR et al (2024) Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403:1460\u20131471. https:\/\/doi.org\/10.1016\/S0140-6736(24)00319-2","journal-title":"Lancet"},{"key":"2744_CR46","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V et al (2023) Lymphodepletion -an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 14:1303935. https:\/\/doi.org\/10.3389\/fimmu.2023.1303935","journal-title":"Front Immunol"},{"key":"2744_CR47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3485","author":"AQ Lee","year":"2024","unstructured":"Lee AQ, Hao C, Pan M et al (2024) Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3485","journal-title":"Clin Cancer Res"},{"key":"2744_CR48","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/bit.28389","volume":"120","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zah E, Arbelaez C et al (2022) A closed, autologous bioprocess optimized for TCR-T cell therapies. Biotechnol Bioeng 120:1809\u20131821. https:\/\/doi.org\/10.1002\/bit.28389","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"2744_CR49","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","volume":"13","author":"A Gyurdieva","year":"2022","unstructured":"Gyurdieva A, Zajic S, Chang YF et al (2022) Biomarler correlated with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat Commun 13(1):5296. https:\/\/doi.org\/10.1038\/s41467-022-32491-x","journal-title":"Nat Commun"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02744-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:04:20Z","timestamp":1745301860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02744-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2744"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02744-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no conflict of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board was waived due to the nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}